CJC-1295 With vs Without DAC: What the Difference Actually Is

CJC-1295 is sold in two forms that look nearly identical on a label but behave very differently in the body. One carries a “DAC” (Drug Affinity Complex); the other, sold as CJC-1295 without DAC — also called modified GRF 1-29, or mod-GRF 1-29 — does not. Both are analogues of growth-hormone-releasing hormone (GHRH), the signal that tells the pituitary to release growth hormone (GH). The single structural difference between them drives almost everything that matters about dosing, timing, and the GH pattern each produces.

The DAC is the whole story

The DAC is a chemical add-on that lets the peptide bind covalently to albumin, the most abundant protein in blood. That tether keeps the molecule circulating instead of being cleared within minutes. In the pivotal early study — Teichman and colleagues, published in the Journal of Clinical Endocrinology & Metabolism in 2006 — CJC-1295 with DAC had an estimated half-life of 5.8 to 8.1 days in healthy adults. A single injection raised mean GH by roughly 2- to 10-fold for six or more days and IGF-1 by 1.5- to 3-fold for 9–11 days; weekly or biweekly dosing kept IGF-1 elevated for up to 28 days.

The DAC extends CJC-1295’s half-life to about 6–8 days, versus roughly half an hour for the no-DAC version — the same modification that turns a brief GH pulse into a sustained days-long elevation.

The no-DAC version has no albumin anchor, so it clears quickly — a half-life on the order of minutes (commonly cited near 30). Instead of a sustained elevation, it produces a short, sharp GH pulse that fades fast, which is closer to the body’s natural pulsatile secretion. That is precisely why mod-GRF 1-29 is dosed frequently (often multiple times a day) and usually paired with a GH-releasing peptide such as ipamorelin to amplify each pulse.

DAC vs No-DAC at a glance

	CJC-1295 with DAC	CJC-1295 without DAC (mod-GRF 1-29)
Half-life	~5.8–8.1 days (Teichman 2006)	~minutes (~30 min commonly cited)
Dosing frequency	Weekly / biweekly	Multiple times daily
GH pattern	Sustained, days-long “bleed”	Brief, pulsatile spike
Typically paired with	Used alone	A GHRP (e.g. ipamorelin)
Human evidence	Early-phase PK/safety only	Essentially none directly

Why it matters

The sustained “GH bleed” from the DAC version is often marketed as an advantage, but constant elevation departs from the natural pulsatile rhythm that a short-acting peptide preserves — and it is not clear that either pattern delivers the body-composition or anti-aging results commonly claimed.

The honest picture is that human data is very limited. What exists is mostly early-phase pharmacokinetic and safety work on the DAC form, showing it raises GH and IGF-1 — not that it improves fat loss, muscle, recovery, or longevity. CJC-1295 was dropped in development (a Phase II trial recorded a participant death, attributed to pre-existing coronary disease and deemed unrelated), and it is not FDA-approved for any use. Regulators have flagged nonclinical findings including injection-site necrosis. It is also prohibited by WADA at all times under category S2.

The takeaway

The DAC is the only meaningful difference, and it is a big one: it converts a fleeting GH pulse into a multi-day elevation, which is why the two versions are dosed so differently. But “different pharmacokinetics” is not “proven benefit.” For either form, controlled human outcome data is absent, neither is FDA-approved, and both are banned in sport. Treat the confident dosing charts online as marketing, not evidence.

Sources

• Teichman et al., “Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults,” JCEM, 2006
• CJC-1295, Wikipedia (DAC mechanism, development history, regulatory status)
• BSCG, “CJC-1295 Use in Sports and Military Rules Explained” (WADA S2 status, DAC vs no-DAC half-lives, FDA status)